This trial is evaluating whether Treatment will improve 1 primary outcome and 1 secondary outcome in patients with Cystitis, Interstitial. Measurement will happen over the course of 3 months.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Routine treatment is unlikely to cause harm in the community; however, there is little prospect of benefit for people who have risk factors for recurrent infections.
About 250,000 cases of bladder infection in people >5 years of age and 25,000 cases in children and adults are reported in year 2000 annually.
Urine tests for leukocyturia and bacterial contamination in urine should reassure the patient that they do not require antibiotics. For patients who develop persistent cystitis, some clinicians are increasingly recommending surgical removal or biopsy of the abscess.
The causes of interstitial cystitis are diverse and may include bacterial, viral, autoimmune, and idiopathic diseases. Current research suggests bladder infections and a history of urinary tract infections are important factors.
Data from a recent study indicates an important relationship between cystitis and interstitial cystitis, and points toward the necessity to provide careful evaluation in these patients, especially in order to reduce the chance of misdiagnosis leading to inappropriate, potentially burdensome treatment.
The combination of urinary signs of infection with signs of interstitial cystitis may suggest the possibility of a more serious condition. Urinary signs of infection should be evaluated.
Recent findings, we show that it is safe to treat patients with cystitis, interstitial with antibiotic treatment on a daily basis. In some cases, the therapy needs to be prolonged or changed, depending on symptoms and progress.
A direct family relationship between CIII and other urological disorders is suggested, which implicates that cystitis, interstitial is a non-genetic urological disorder which can be transmitted from family to family. We suggest that cystitis, interstitial may be caused by an intra-urolological factor and cystitis, interstitial run in families are a new kind of urinary disorders.
The treatment of cystitis, interstitial, leads to significant improvements in quality of life. The improvement is more significant for female patients and the patients with worse symptoms at the beginning of treatment. However, in male patients, the symptomatic score was not affected by the treatment.
Most reported treatments for EI and CCF seem to be relatively straightforward in terms of the treatments that are actually used. The treatment regimens prescribed by gynaecologists in this study were typical of the gynaecological treatment of CCF and were generally consistent with the gynaecological treatments of EI in the preceding literature.
The use of antibiotics in children with uncomplicated bladder infections reduced by 30% the rate of febrile urinary tract infection in the next year. A similar benefit occurred for those with the bacterial species that were most often encountered. A randomized controlled trial of antibiotics must be considered as a control group and not as a treatment.
The benefits of clinical trials may be more applicable among specific populations, such as women with recurrent or new-onset interstitial cystitis, as opposed to those with existing interstitial cystitis.